BRAF and autoimmune disease: This cohort consisted of 119 patients with known unfavorable characteristics such as brain metastases (stage M1d disease), being older individuals (≥70 years old), poor performance status (≥2 ECOG), prior treatment, BRAF V600 mutation and the presence of an active autoimmune disorder requiring systemic steroid treatment.